abstract BACKGROUND AND OBJECTIVE: Continuous antibiotic prophylaxis (CAP) is recommended to prevent urinary tract infections (UTIs) in newborns with antenatal hydronephrosis (HN). However, there is a paucity of high-level evidence supporting this practice. The goal of this study was to conduct a systematic evaluation to determine the value of CAP in reducing the rate of UTIs in this patient population.
Antenatal hydronephrosis (HN) is one of the most common congenital anomalies, occurring in 1% to 5% of all pregnancies. 1 Continuous antibiotic prophylaxis (CAP) has been empirically recommended for newborns who have antenatal HN in an attempt to reduce the rate of urinary tract infections (UTIs) during the first 2 years of life. 2, 3 Given the 2009 American Urological Association update and the 2010 Society for Fetal Urology (SFU) consensus statement on HN, it seems prudent to consider use of CAP in "high-risk" populations, such as those with higher grades of HN. 1, 3, 4 Nevertheless, this practice is admittedly based on limited data and heavily reflects expert opinion.
Previous reports have suggested that infants who have moderate to severe HN are at a higher risk of developing UTIs, thus supporting the use of prophylactic measures. [4] [5] [6] However, recent studies have provided contradictory information, suggesting that infants with all grades of HN can be safely managed without CAP, with UTI rates as low as 4%. [7] [8] [9] With increasing concerns about bacterial antibiotic resistance and unknown long-term effects, a growing number of physicians and parents are challenging the necessity and effectiveness of CAP in preventing UTIs. Ultimately, the issue becomes a risk/benefit question, which heavily relies on whether daily antibiotic administration decreases the risk of infections and if this risk reduction is enough to translate into a clinically significant intervention.
To evaluate the current evidence on CAP effectiveness and address the contemporary status of clinical equipoise, we conductedasystematicreviewofthepertinent literature to assess the impact of CAP on UTI rates in infants who have antenatal HN.
METHODS

Eligibility Criteria
Studies fulfilling the following eligibility criteria were included: (1) primary diagnosis of antenatal HN; (2)all subjects aged ,2 years; (3) intervention arms include CAP, no treatment, or both; (4) reported rate of UTI; (5) reported number of patients who underwent voiding cystourethrogram (VCUG); (6) HN grade according to the SFU classification and/or anteroposterior diameter (APD) of the renal pelvis; and (7) publication date between 1990 and 2010. Exclusion criteria included case reports, case series with ,5 subjects, and review articles. No language restrictions were imposed.
Identification of Studies
A comprehensive and systematic search of 4 databases (Medline, Embase, CINAHL, and CENTRAL) was conducted in duplicate. When possible, the search used MeSH terms, and the strategy was devised with an information specialist at our institution. Gray literature was searched by using key words in PapersFirst and ProceedingsFirst databases, along with a hand search of Dialogues in Pediatric Urology. The reference list of prominent review articles was crossreferenced to minimize omissions. Lastly, a content expert review of the final list of included studies was conducted.
Screening and Assessing for Eligibility
Two reviewers screened titles and abstracts of the identified studies from the electronic search to select all citations that might contain the comparisons of interest. Subsequently, 2 independent reviewers conducted fulltext screening of identified pertinent articles as well as those obtained by hand-search review of reference lists. All screening results were reviewed for concordance, and all disagreements were resolved by a third reviewer and content expert. The following languages were included: English, French, Italian, Dutch, Portuguese, Spanish, German, Chinese, and Arabic. Study selection was not blinded; concealment has been shown to have no significant effect on the final results of systematic reviews. 10 
Assessment of Methodologic Quality
Critical appraisal and assignment of a level of evidence for the included studies was conducted by 2 independent reviewers by using a quality assessment instrument adopted from Elyas et al, 11 modified to fit the objectives of this study (Table 1 ). All discrepancies were resolved through third-party review of the methodology.
Study rating was determined by dividing the number of criteria met (indicated as "Yes") by the total number of quality assurance criteria in the instrument (n = 13), obtaining a percentage result. For scoring purposes, we have assumed equal weight for all questions. The data were then segregated into studies that met ,25% of the quality criteria (very low methodologic quality), between 25% and 49% (low quality), between 50% and 74% (moderate quality), and .75% of the criteria (high quality).
Extraction of Data
Data extraction was completed in duplicate and reviewed for accuracy and quality. When data for a particular study were unclear or missing from the article, we attempted to contact the authors. Unfortunately, in cases of missing information, we were unable to obtain any additional information.
Assessment of Agreement
The k (k) statistic was used to examine the extent of agreement between individuals who determined study eligibility and to evaluate interobserver agreement in methodologic quality scores. A priori, we chose a criterion of k $ .65 to indicate adequate agreement. 12 
Outcome Measures
The SFU system was used to grade postnatally confirmed HN. Secondary analyses chosen a priori were as follows: occurrence of a UTI in patientswith concomitant vesicoureteral reflux (VUR) versus no VUR, and occurrence of a UTI in females compared with males. Although we initially planned on assessing UTI rates in circumcised versus uncircumcised boys, data from the available studies were insufficient to allow for this particular comparison.
Statistical Analyses
We anticipated that the search results would yield case series (single group retrospective or prospective studies) reporting the overall proportion of UTI and some comparative data reporting the proportion of UTI for CAP status (yes versus no) or HN grade (high versus low). Therefore, due to the inherent heterogeneity of the case series and observational designs, we planned a priori to use random effects models to account for between-study heterogeneity.
Odds ratios (OR) and 95% confidence intervals (CIs) for the primary outcome
FIGURE 1
Selection process for study inclusion (PRISMA flow diagram).
(UTI) were calculated whenever frequency data were available. We included in our primary meta-analyses any study that reported a rate of UTI, obtaining pooled estimates for infants with low-and high-grade HN, patients on CAP versus not, infants with and without VUR, and girls compared with boys. We applied the random effects model by using the DerSimonian-Laird method due to the inherent heterogeneity of case series to estimate the pooled weighted UTI proportion of the included studies in these meta-analyses. The pooled weighted proportion was calculated as the back-transformation of the weighted mean of the transformed proportions, using DerSimonian-Laird (1986) weights for the random effects model. StatsDirect software version 2.7.8 (www.statsdirect.com) was used to calculate the pooled weighted proportions.
When deemed appropriate, we conducted a secondary meta-analysis of any study that reported a direct comparison of UTI rates for infants with low-and high-grade HN, patients on CAP versus not, and girls compared with boys. We performed a random effects model by using an inverse variance method to calculate the OR with 95% CIs for the primary outcome (UTI) for CAP status (yes versus no), HN grade (high versus low), and gender (girls versus boys). RevMan version 5.1 (Review Manager, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011) was used for calculating ORs. A P value of .05 was set for statistical significance. The number needed to treat was also estimated to prevent the primary outcome (UTI) by receiving CAP.
Evaluation of Heterogeneity
Heterogeneity between studies was quantified by using the I 2 statistic, which represents the percentage of total variation across included studies that is due to heterogeneity rather than chance. Publication bias was graphically assessed by constructing funnel plots depicting precision (measured according to sample size) against the logit of the event rate.
Secondary meta-analyses were selectively conducted for studies that reported a direct comparison between UTI rates according to the grade of HN (low versus high) and CAP use (yes versus no) to reduce clinical heterogeneity. Methodologic heterogeneity was explored by conducting sensitivity analyses comparing low-versus highquality articles according to our quality appraisal criteria.
RESULTS
Included Studies
Our literature search identified 1681 potentially relevant citations. After screening, a total of 309 articles underwent full-text review, and 21 of these citations 4-7,13-29 proved eligible for inclusion and final analysis (Fig 1) . The weighted k for overall agreement between reviewers for the final eligibility decision was 0.85 (95% CI: 0.57-1.00). None of the included studies was a randomized clinical trial, and thus all were observational. Thirteen studies had a retrospective design 4, 6, 7, 16, [18] [19] [20] [21] [22] [23] 25, 26, 28 and 8 were prospective. 5, [13] [14] [15] 17, 24, 27, 29 
Patient Characteristics
Patient characteristics for the included studies are summarized in Tables 2 and 3 . The total number of infants in these studies was 3876. Given the inconsistencies in available data provided by each study, we conducted analyses including only complete relevant information to obtain pooled estimates that would specifically address the objectives of our review.
Study Quality
Five studies were judged to be of high methodologic quality, 5, 6, 19, 23, 29 8 to be of moderate quality, 4, 7, 15, 20, [25] [26] [27] [28] 5 studies to be of low quality, 14, 17, 18, 21, 22 and 3 studies to be of very low quality 13, 16, 24 ( Table 4) . Agreement between reviewers in assessment of study quality was high (k ..9). Table 6 , n = 507 infants 4, 6, 7, 20, 23, 25 ). The estimated number needed to treat to prevent UTIs in infants with high-grade HN receiving CAP was 7, which represents a measure of benefit (ie, that prescribing CAP to 7 infants with high-grade HN translates into preventing 1 UTI).
VUR and Rates of UTI
The pooled UTI rate for infants with VUR was 22.8% (95% CI: 9.7-39.4) compared with the pooled rate of 9.3% (95% CI: 3.1-18.5) for patients without VUR (P = .31) (Figs 4 A and B) . We could not extract sufficient data to examine the association between VUR and UTI stratified according to HN grade or use of CAP.
Gender and Rates of UTI
A total of 8 studies [4] [5] [6] [7] 16, 18, 20, 22 reported on UTI rates according to gender. UTI rates were similar in boys and girls with antenatal HN (15% vs 18.9%; P = .21) (Fig 5) . We could not extract (,25%%) 3 (14) sufficient data to compare UTI rates between girls and boys based on HN grade or addressing circumcision status.
Heterogeneity and Publication Bias
To reduce heterogeneity, a random effects model was followed when conducting the current meta-analysis, limited to studies reporting a direct comparison between low-versus highgrade HN (Fig 6) . The pooled OR was 5.8 (95% CI: 3.9-8.7), suggesting that highgrade HN was significantly associated with a higher rate of UTI. To adjust for potential confounding effects of VUR and CAP on UTI, we have chosen to display the percentage of VUR and CAP patients in Fig 6. To further validate these findings, a sensitivity analysis was conducted, comparing moderate versus high methodologic quality articles. The pooled OR for high-quality studies (6.3 [95% CI: 3.9-9.5]) also suggests that high-grade HN was significantly associated with higher UTI rates (Fig 7) .
When we conducted a separate metaanalysis including only studies that compared CAP use versus no use of CAP, we obtained a pooled OR of 1.7 (95% CI: 1.1-2.8), indicating that patients receiving CAP had significantly lower UTI rates (Fig 8) .
A funnel plot was created, involving 17 studies that reported UTI rates. [5] [6] [7] 13, 14, 16, [18] [19] [20] [21] [22] [23] 25, 26, 28, 29 The distribution of studies is scattered over the 4 quadrants of the graph, suggesting a lack of publication bias (Fig 9) .
DISCUSSION
With the widespread practice of routine prenatal ultrasound, the number of fetuses with detected HN has increased commensurately. Management of the many patients who have persistent HN In general, physicians prescribe CAP to reduce the risk of UTI in infants who have antenatal HN and to prevent UTIassociated morbidity as well as longterm complications of renal damage. 34 Nevertheless, the ultimate decision to start an infant on CAP currently centers on parental acceptance aligning with individual health care provider and/or institution protocols. Due to the paucity of published data, treatment philosophy plays an important role. Thus, the decision is based on partially defined risks and benefits, heavily affected by the perception of what is more valuable: potentially preventing pyelonephritis and sepsis or accepting the administration of a drug that may provide little benefit but can be associated with adverse effects and bacterial resistance. Conceptually, it would make sense to tailor the prescription of CAP based on specific patient characteristics that affect the odds of experiencing the outcome of interest. However, consensus on what constitutes a risk factor for UTI warranting CAP in this population has yet to be determined. To date, there is limited information on the topic.
All of the reviewed publications have recognized important shortcomings in terms of study design, number of patients evaluated, inclusion and exclusion criteria, definition of events, and monitoring and assessment of compliance. Thus, the information gathered from each of them on an individual basis is difficult to bring into clinical practice. In addition, the findings from relevant series are at times inconsistent. Coelho et al 5 found that girls with VUR or urinary tract obstruction had a higher risk of UTI during follow-up and recommended CAP and close clinical monitoring. Estrada et al 28 observed that in patients with postnatal persistent grade II HN, identification of VUR through a VCUG and use of CAP significantly reduced the risk of febrile UTI. Conversely, some authors have argued that CAP does not change the risk of UTI in specific patient populations. Roth et al 7 conducted a retrospective study of patients with SFU grade III/IV HN and, based on an overall low baseline rate of UTI (4%), recommended against widespread use of CAP for all infants with antenatal HN. Similarly, in a recent prospective study, Islek et al 9 concluded that CAP use is not indicated in infants with ureteropelvic junction obstruction, regardless of its severity, as the risk of UTI was minimal in this group.
Given these discrepancies, our goal was to conduct a systematic review, aiming to summarize the current evidence regarding the use of CAP in antenatal HN patients. In addition, this exercise sought to further analyze direction and magnitude of potential treatment effects while highlighting deficiencies in knowledge that should be considered for future studies. To our knowledge, no similar reviews have been published on this particular topic thus far. Our strict eligibility criteria for included studies have allowed us to gather a rather homogeneous patient population, summarizing information on a relatively large number of infants identified antenatally and followed up for a minimum of 12 months after birth. HN. Nevertheless, it should also be noted that due to limitations of the reported data in the studies included, the effect of important variables (eg, VUR, gender) could not be properly evaluated.
As with most meta-analyses, the current report has important limitations. The 
FIGURE 5
UTI rates in infants with antenatal HN grouped according to gender. IV, inverse variance.
FIGURE 6
Meta-analysis on UTI rate in high-grade versus low-grade HN. AHN, antenatal HN. M-H, Mantel-Haenszel.
most notable is the unavoidable restriction to observational studies because we could not identify any randomized controlled trials examining the relationship between CAP and UTIs in infants with antenatal HN. This finding reflects the state of current evidence on the topic of CAP and antenatal HN. Methodologic and analytical issues related to observational studies of different quality have to be carefully considered and kept present when aggregating data and placing these outputs in perspective. Even if all the included nonexperimental studies were of high methodologic quality, the resultant level of evidence would be moderate. In addition, it is possible that our estimates of UTI rates were biased due to restricted analysis of the 6 studies with data on direct comparison of UTI rates between infants with low-and high-grade HN. Nevertheless, the followed strategy allowed for optimizing statistical power (by virtue of a larger sample size) within a more homogeneous patient population, ultimately combining results and providing a common measure of effect size. Moreover, the format in which data were presented varied widely between studies. We elected to group infants based on SFU grade to be able to make meaningful comparisons between the studies. However, inconsistent grading of HN (a situation that was more notable in older studies) made it difficult to compare all patient populations. As previously indicated, some studies were excluded from the final analysis because the provided measurements could not be translated into SFU grading. Similarly, although most articles reported on occurrence of antenatal HN in individual patients, some articles reported their results in renal units without correlating these data to the number of patients affected (as shown in Table 2 ).
Due to the paucity of data, we were unable to comment on the association between antenatal HN concurrent with VUR and UTI, and gender effect on UTI, adjusted according to HN grade. Associations between the primary outcome and isolated HN (ureteropelvic junction obstruction-like) or hydroureteronephrosis (primary megaureter) were often difficult to analyze because the included articles had not
FIGURE 7
Sensitivity analysis comparing high-quality versus moderate-quality studies. AHN, antenatal HN.
FIGURE 8
Meta-analysis on UTI rate in CAP use versus no CAP use.
consistently provided UTI rates discriminated according to etiology. In an attempt to assess UTI rates solely in patients with hydroureteronephrosis without VUR (primary megaureter), we obtained data from 4 pertinent studies [4] [5] [6] [7] as displayed in Fig 10. The pooled UTI rate was 34% (95% CI: 14-58), significantly higher than the rate of all patients with high-grade HN (23.3% [95% CI: 3.7-12]), suggesting that these patients might be at an even higher risk of developing UTI and could benefit from administration of CAP.
Finally, in the same way, we were unable to draw conclusions about the impact of circumcision on UTI rates; UTI data on circumcised males were only available for 10 boys in 2 studies.
Despite those limitations, we believe there is value in the current report. We present compelling evidence to suggest that infants who have highgrade HN who are not receiving CAP are at a significantly higher risk of UTI when compared with infants who have high-grade HN who are receiving prophylaxis. This information is a first step toward tailoring our approach for patients with antenatal HN, which could be selectively favored in cases of high-grade HN. This systematic review corroborates the presence of clinical equipoise regarding the postnatal management of infants with antenatal HN due to the lack of sound evidence supporting or disproving the effectiveness of CAP to prevent UTIs in this patient population.
CONCLUSIONS
This systematic review implies that offering CAP to 7 infants who have high-grade HN would prevent 1 UTI, suggesting value in this subgroup of patients. Given the existing data, the effect of VUR, gender, and circumcision on UTI could not be determined. Current lack of best practice guidelines in the pediatric urology community, coupled with the controversial literature surrounding this topic, calls for prospective, randomized placebo-controlled trials to investigate the effect of CAP in reducing UTI rates in infants with antenatal HN.
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FIGURE 9
Funnel plot portraying precision of included studies [4] [5] [6] [7] 13, 14, 16, [18] [19] [20] [21] [22] [23] 25, 26, 28, 29 with regard to the UTI rates.
FIGURE 10
UTI Rates in infants with hydroureter and no VUR. Pooled UTI rate is 34% (95% CI: 14-58), I 2 (inconsistency) = 87% (95% CI: 61.7-93.2).
